Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros

País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Gastroenterol Hepatol ; 46(2): 92-101, 2023 Feb.
Artículo en Inglés, Español | MEDLINE | ID: mdl-35292333

RESUMEN

AIM: The aim of this study was to evaluate and compare the presence and impact of Gastrointestinal (GI) symptoms, physical and psychological disturbances on patients' QoL after sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB) and biliopancreatic diversion with duodenal switch (BPD/DS). METHODS: A prospective, observational, cross-sectional, comparative study was carried-out. GI symptoms and patients' QoL were evaluated by the SF-36 questionnaire and the GI quality of life index (GIQLI). Correlation between GI symptoms, psychological disturbances and QoL scores was analysed. RESULTS: 95 patients were included (mean age 50.5 years, range 22-70; 76 females). Presence of GI symptoms was a consistent finding in all patients, and postprandial fullness, abdominal distention and flatulence had a negative impact on patients' QoL. Patients after SG showed a worsening of their initial psychological condition and the lowest QoL scores. Patients after RYGB showed the best GI symptoms-related QoL. CONCLUSIONS: Both restrictive and malabsorptive bariatric surgical procedures are associated with GI symptoms negatively affecting patients' QoL. Compared to SG and BPD/DS, patients after RYGB showed the best GI symptoms-related QoL, which can be used as additional information to help in the clinical decision making of the bariatric procedure to be performed.


Asunto(s)
Cirugía Bariátrica , Obesidad Mórbida , Adulto , Anciano , Femenino , Humanos , Persona de Mediana Edad , Adulto Joven , Cirugía Bariátrica/efectos adversos , Cirugía Bariátrica/métodos , Estudios Transversales , Gastrectomía/métodos , Obesidad Mórbida/cirugía , Estudios Prospectivos , Calidad de Vida
2.
Int J Mol Sci ; 21(24)2020 Dec 09.
Artículo en Inglés | MEDLINE | ID: mdl-33316953

RESUMEN

The extracellular vesicles (EVs) have emerged as key players in metabolic disorders rising as an alternative way of paracrine/endocrine communication. In particular, in relation to adipose tissue (AT) secreted EVs, the current knowledge about its composition and function is still very limited. Nevertheless, those vesicles have been lately suggested as key players in AT communication at local level, and also with other metabolic peripheral and central organs participating in physiological homoeostasis, and also contributing to the metabolic deregulation related to obesity, diabetes, and associated comorbidities. The aim of this review is to summarize the most relevant data around the EVs secreted by adipose tissue, and especially in the context of obesity, focusing in its protein cargo. The description of the most frequent proteins identified in EVs shed by AT and its components, including their changes under pathological status, will give the reader a whole picture about the membrane/antigens, and intracellular proteins known so far, in an attempt to elucidate functional roles, and also suggesting biomarkers and new paths of therapeutic action.


Asunto(s)
Tejido Adiposo/metabolismo , Vesículas Extracelulares/metabolismo , Obesidad/metabolismo , Animales , Humanos , Proteoma/genética , Proteoma/metabolismo
3.
Surg Obes Relat Dis ; 17(10): 1766-1772, 2021 10.
Artículo en Inglés | MEDLINE | ID: mdl-34332909

RESUMEN

BACKGROUND: Gastrointestinal anatomical changes after restrictive and malabsorptive bariatric surgery lead to important disturbances in the process of digestion and absorption of nutrients and could lead to exocrine pancreatic insufficiency (EPI). OBJECTIVE: The aim of the present study was to evaluate and to compare pancreatic function and the dynamic of digestion and absorption of nutrients after restrictive and malabsorptive bariatric surgical procedures. SETTING: University Hospital of Santiago de Compostela, Santiago de Compostela, Spain. METHODS: A prospective, observational, cross-sectional, comparative study of patients after sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB), and biliopancreatic diversion with duodenal switch (BPD/DS) was carried out. Patients with obesity who did not undergo surgery were included as control group. Pancreatic function and the dynamic of digestion and absorption of nutrients were evaluated by the 13C-mixed triglyceride (13C-MTG) breath test. Six-hour 13C-cumulative recovery rate (13C-CRR), 13C exhalation peak, and 1-hour maximal 13C-CRR were calculated. RESULTS: One-hundred five patients were included (mean age, 49.8 yr; 84 women). Six-hour 13C-CRR was significantly reduced after BPD/DS (P < .001) but not after SG and RYGB. EPI was present in 75% of patients after BPD/DS, 8.3% of patients after RYGB, and 4.3% of patients after SG. Compared with the control group who did not undergo surgery, digestion and absorption of nutrients tended to occur earlier after SG, whereas it was delayed after RYGB and mainly after BPD/DS (P < .001). CONCLUSION: Bariatric surgery significantly alters the dynamic of the digestive process. EPI is very common after BPD/DS, frequent after RYGB, and less frequent after SG. This information is clinically relevant since EPI is a treatable condition associated with symptoms, nutritional deficiencies, and complications.


Asunto(s)
Cirugía Bariátrica , Desviación Biliopancreática , Derivación Gástrica , Obesidad Mórbida , Páncreas/fisiopatología , Cirugía Bariátrica/efectos adversos , Estudios Transversales , Digestión , Femenino , Gastrectomía , Derivación Gástrica/efectos adversos , Humanos , Masculino , Persona de Mediana Edad , Obesidad Mórbida/cirugía , Estudios Prospectivos
4.
Obes Surg ; 31(1): 431-436, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-33051790

RESUMEN

BACKGROUND: Duodenal switch (DS) is considered one of the most effective bariatric techniques for long-term weight and comorbidity control. After these operations, some patients may get severe complications related to malnutrition and a few of them may need surgical revision. Lengthening the common channel (CC) is usually the solution: changing the Roux anastomosis or with a side-to-side anastomosis (kissing X). We propose that when simplified construction of the DS is used, conversion to single anastomosis DS (SADI-S/OADS) is an easy and safe choice. OBJECTIVES: To evaluate the safety and effectiveness of conversion from DS to SADI-S in cases of malnutrition. METHODS: We report three patients with severe malnutrition after a DS at 9, 74, and 84 months. One of them had also liver failure related to alcohol abuse and malnutrition. Laparoscopic reoperations included a new ileo-ileal anastomosis and takedown of the Roux-en-Y anastomosis with the aim of lengthening the CC. RESULTS: All three patients were successfully converted by laparoscopy. After a median follow-up of 54.6 months [32-76 months], all of them had moderate weight regain and returned to normal biochemical nutritional parameters. Two patients with type 2 diabetes (T2DM) before DS had complete remission before conversion; one of them had recurrence of T2DM after conversion. The patient with liver failure improved significantly after conversion. CONCLUSIONS: Conversion from DS to SADI-S/OADS is a simple operation with excellent results in resolving malnutrition in those patients. However, weight regain and recurrence of comorbidities may arise.


Asunto(s)
Desviación Biliopancreática , Diabetes Mellitus Tipo 2 , Laparoscopía , Desnutrición , Obesidad Mórbida , Anastomosis Quirúrgica , Diabetes Mellitus Tipo 2/cirugía , Duodeno/cirugía , Gastrectomía , Humanos , Desnutrición/etiología , Obesidad Mórbida/cirugía , Pérdida de Peso
5.
Clin Ther ; 42(2): e1-e12, 2020 02.
Artículo en Inglés | MEDLINE | ID: mdl-32005534

RESUMEN

PURPOSE: The aim of this study was to evaluate the effectiveness and safety of combination therapy with a sodium-glucose cotransporter-2 (SGLT2) inhibitor and a glucagon-like peptide-1 receptor agonist (GLP1RA) in patients with inadequately controlled type 2 diabetes. METHODS: A retrospective search of electronic prescriptions of patients undergoing GLP1RA and SGLT2 inhibitor combination therapy was conducted. Once the patients had been identified, demographic data, blood and urine analyses (glycosylated hemoglobin [HbA1c], glucose, renal function, albuminuria, lipid profile, liver enzymes, and uric acid), physical examination (weight, body mass index, and blood pressure), and adverse effects were obtained from their electronic clinical records according to each of the following 3 periods: before the initiation of the combination, the first visit after initiation, and the last available visit. The influence of the duration of diabetes and the drug combination sequence on the effectiveness of the treatment was also analyzed. Statistical analysis was performed with SPSS version 21.0 (IBM SPSS Statistics, IBM Corporation, Armonk, New York). Quantitative variables are presented as mean and SD and were compared by using the Student t test, one-way ANOVA, or repeated measures ANOVA with Bonferroni correction. Categorical variables are expressed as percentages and were compared by using the χ2 test. RESULTS: A total of 212 patients were included, with women accounting for 52.4%. The mean age (SD) of the population was 61.5 (9.6) years. A significant reduction in HbA1c (-12 mmol/mol [-1.1%]) was observed with combined therapy (P < 0.001). The target of HbA1c <53 mmol/mol (<7%) was achieved in 42% of the participants. Mean weight loss was -3.5 kg, and almost 40% of the patients attained the weight loss goal of ≥5% (P < 0.001 in all analyses). Transaminase levels and renal parameters also improved. These benefits persisted over time and bore no relation to the evolution of diabetes. Simultaneous initiation of a combination of a GLP1RA and SGLT2 inhibitor led to faster weight loss and a greater decrease in HbA1c than when they are used sequentially; however, the long-term benefits in terms of metabolic control were similar. Adverse events were rare, and a tendency for a reduced insulin dose was observed. IMPLICATIONS: The findings of this study reveal the combined benefits of a GLP1RA and SGLT2 inhibitor in real-world clinical practice. In general, the combined treatment was well tolerated, and few adverse events were detected.


Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Receptor del Péptido 1 Similar al Glucagón/antagonistas & inhibidores , Hipoglucemiantes/uso terapéutico , Inhibidores del Cotransportador de Sodio-Glucosa 2/uso terapéutico , Anciano , Diabetes Mellitus Tipo 2/sangre , Quimioterapia Combinada , Femenino , Hemoglobina Glucada/análisis , Humanos , Masculino , Persona de Mediana Edad , Pérdida de Peso/efectos de los fármacos
6.
Nutr Hosp ; 35(3): 511-518, 2018 Jun 07.
Artículo en Inglés | MEDLINE | ID: mdl-29974755

RESUMEN

INTRODUCTION: home enteral nutrition (HEN) has undergone an important development; however, there is a notable lack of information with regard to its incidence and characteristics. OBJECTIVES: our aim was to assess the state of HEN in our area. METHODS: an observational, prospective study, involving all patients who had initiated HEN in the Nutrition Unit during a year. Epidemiological, functional, and nutritional evolution of the patients was described and incidence of HEN was calculated. RESULTS: HEN incidences totalled 229/100,000 inhabitants/year. The HEN population in our area was characterized by the aged and a high frequency of comorbidity and functional limitations. Neurological and oncological diseases accounted for 50% of indications. The remaining cases were malnourished patients who had received short periods of HEN after hospitalization or a hip fracture. Oral supplements (60%) with standard and hypercaloric formulas were used the most. At baseline, 75% of the patients suffered from malnutrition. During the follow-up, patients showed weight gain (1.6%), an increase in the percentage of normal weight and overweight (from 74% to 82.7%, p = 0.001) and a reduction in pressure ulcers (15.7% vs10.3%, p < 0.001). The median duration of HEN was 8.5 months. Only a quarter of the patients experienced complications (mostly mild gastrointestinal complications); 43.1% had died at the end of the follow-up. CONCLUSIONS: in our area, the HEN incidence was much higher than those described in the literature. HEN appears to be a safe therapy with few complications that improves the nutritional status of the patients, even with short periods of administration.


Asunto(s)
Nutrición Enteral/estadística & datos numéricos , Factores de Edad , Anciano , Anciano de 80 o más Años , Comorbilidad , Nutrición Enteral/efectos adversos , Nutrición Enteral/mortalidad , Femenino , Servicios de Atención de Salud a Domicilio , Humanos , Incidencia , Masculino , Desnutrición/epidemiología , Desnutrición/terapia , Persona de Mediana Edad , Estudios Prospectivos , España/epidemiología
7.
Nutr Hosp ; 32(1): 215-21, 2015 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-26262720

RESUMEN

INTRODUCTION: home artificial nutrition (HAN) is a growing therapy, but the absence of obligatory registries complicates the calculation of its real economic burden. The aim of this study was to assess the state and economic impact of HAN in our health area. METHODS: an observational, prospective study was designed to calculate the cost of nutritional formulas and materials in patients who initiated HAN in the nutrition unit during a year. RESULTS: we included 573 new patients with HAN during the study period, 60% of whom were treated with oral supplements. The median daily cost of oral HAN was 3.65 (IQR 18.63) euros compared to a cost of 8.86 (IQR 20.02) euros for enteral-access HAN. The daily expenditure per 1 000 kcal of diet was higher for patients on oral HAN than for patients with tubes (5.13 vs. 4.52 euros, p < 0.001). The median cost of the complete HAN treatments during the study period was also calculated (186.60 euros and 531.99 euros for oral and tube HAN, respectively). The total estimated cost for all patients who initiated HAN in the study period was around one million euros. CONCLUSIONS: HAN represented an important economic burden in our health area, but the estimated daily cost of HAN was moderate, probably because of the high frequency of oral HAN, the adjusted treatments, and the centralized dispensation by the hospital pharmacy.


Introducción: la nutrición artificial domiciliaria (NAD) es una terapia en creciente desarrollo, pero la ausencia de registros obligatorios hace difícil calcular la carga económica que implica. Nuestro objetivo es evaluar el estado y el impacto económico de la NAD en nuestra área sanitaria. Métodos: estudio observacional y prospectivo diseñado para estimar el gasto en fórmulas y materiales nutricionales en los pacientes que iniciaron NAD durante 1 año. Resultados: se incluyeron 573 pacientes que iniciaron NAD en el período de estudio. El 60% recibieron suplementos orales. La mediana de gasto diario fue de 3,65 (RIC 18,63) euros en la NAD oral y de 8,86 (RIC 20,02) euros en la NAD por acceso enteral. El gasto por 1.000 kcal de dieta fue superior en los pacientes con NAD oral respecto a los pacientes con NAD enteral (5,13 vs. 4,52 euros, p < 0.001). Asimismo se calculó la mediana de gasto completo de los tratamientos durante todo el período de estudio (186,60 euros y 531,99 euros en NAD oral y enteral, respectivamente). Considerando el gasto conjunto de todos los pacientes que iniciaron NAD en el período de estudio, el gasto estimado estaría en torno a un millón de euros. Conclusiones: la NAD representa una importante carga económica en nuestra área sanitaria. Sin embargo, el gasto diario estimado fue moderado, probablemente por la elevada proporción de NAD oral en nuestra muestra, la revisión frecuente de la indicación y la centralización de la dispensación desde el servicio de Farmacia Hospitalaria.


Asunto(s)
Servicios de Atención de Salud a Domicilio/economía , Servicios de Atención de Salud a Domicilio/estadística & datos numéricos , Apoyo Nutricional/economía , Apoyo Nutricional/estadística & datos numéricos , Anciano , Anciano de 80 o más Años , Análisis Costo-Beneficio , Femenino , Alimentos Formulados , Humanos , Masculino , Persona de Mediana Edad , Apoyo Nutricional/métodos , Sistema de Registros , España , Factores de Tiempo
8.
Gastroenterol. hepatol. (Ed. impr.) ; 46(2): 92-101, Feb. 2023. tab, ilus, graf
Artículo en Inglés | IBECS (España) | ID: ibc-226571

RESUMEN

Aim: The aim of this study was to evaluate and compare the presence and impact of Gastrointestinal (GI) symptoms, physical and psychological disturbances on patients’ QoL after sleeve gastrectomy (SG), Roux-en-Y gastric bypass (RYGB) and biliopancreatic diversion with duodenal switch (BPD/DS). Methods: A prospective, observational, cross-sectional, comparative study was carried-out. GI symptoms and patients’ QoL were evaluated by the SF-36 questionnaire and the GI quality of life index (GIQLI). Correlation between GI symptoms, psychological disturbances and QoL scores was analysed. Results: 95 patients were included (mean age 50.5 years, range 22–70; 76 females). Presence of GI symptoms was a consistent finding in all patients, and postprandial fullness, abdominal distention and flatulence had a negative impact on patients’ QoL. Patients after SG showed a worsening of their initial psychological condition and the lowest QoL scores. Patients after RYGB showed the best GI symptoms-related QoL. Conclusions:Both restrictive and malabsorptive bariatric surgical procedures are associated with GI symptoms negatively affecting patients’ QoL. Compared to SG and BPD/DS, patients after RYGB showed the best GI symptoms-related QoL, which can be used as additional information to help in the clinical decision making of the bariatric procedure to be performed.(AU)


Objetivo: El objetivo de este estudio fue evaluar y comparar la presencia e impacto de los síntomas gastrointestinales (GI), los cambios físicos y psicológicos en la calidad de vida (CV) de los pacientes sometidos a tubulación gástrica (TG), bypass gástrico en Y de Roux (BGYR) y derivación biliopancreática con cruce duodenal (DBP/CD). Métodos: Se realizó un estudio prospectivo, observacional, transversal y comparativo. Los síntomas gastrointestinales y la CV de los pacientes fueron evaluados mediante el cuestionario SF-36 y el índice gastrointestinal de calidad de vida (GIQLI). Se analizó la relación entre los síntomas gastrointestinales, los trastornos psicológicos y las puntuaciones de CV. Resultados: Se incluyeron 95 pacientes (edad media: 50,5 años, rango: 22-70; 76 mujeres). La presencia de síntomas gastrointestinales fue un hallazgo constante en todos los pacientes, y la pesadez posprandial, la distensión abdominal y la flatulencia tuvieron un impacto negativo en la CV de los pacientes. Los pacientes después de la TG mostraron un empeoramiento de su estado psicológico inicial y unas puntuaciones más bajas en la CV. Los pacientes después del BGYR presentaron la mejor CV relacionada con los síntomas gastrointestinales. Conclusiones: Los procedimientos de cirugía bariátrica tanto restrictivos como malabsortivos se asocian a síntomas GI que afectan negativamente la CV de los pacientes. En comparación con la TG y la DBP/CD, los pacientes tras el BGYR presentaron la mejor CV relacionada con los síntomas GI, lo que puede utilizarse como información adicional para ayudar en la toma de decisiones clínicas sobre el procedimiento bariátrico a realizar.(AU)


Asunto(s)
Humanos , Masculino , Femenino , Adulto Joven , Adulto , Persona de Mediana Edad , Anciano , Calidad de Vida , Cirugía Bariátrica , Procedimientos Quirúrgicos del Sistema Digestivo , Flatulencia , Gastroenterología , Enfermedades Gastrointestinales , Estudios Prospectivos , Estudios Transversales
9.
Nutr. hosp ; 35(3): 511-518, mayo-jun. 2018. tab, graf
Artículo en Inglés | IBECS (España) | ID: ibc-180104

RESUMEN

Introduction: home enteral nutrition (HEN) has undergone an important development; however, there is a notable lack of information with regard to its incidence and characteristics. Objectives: our aim was to assess the state of HEN in our area. Methods: an observational, prospective study, involving all patients who had initiated HEN in the Nutrition Unit during a year. Epidemiological, functional, and nutritional evolution of the patients was described and incidence of HEN was calculated. Results: HEN incidences totalled 229/100,000 inhabitants/year. The HEN population in our area was characterized by the aged and a high frequency of comorbidity and functional limitations. Neurological and oncological diseases accounted for 50% of indications. The remaining cases were malnourished patients who had received short periods of HEN after hospitalization or a hip fracture. Oral supplements (60%) with standard and hypercaloric formulas were used the most. At baseline, 75% of the patients suffered from malnutrition. During the follow-up, patients showed weight gain (1.6%), an increase in the percentage of normal weight and overweight (from 74% to 82.7%, p = 0.001) and a reduction in pressure ulcers (15.7% vs10.3%, p < 0.001). The median duration of HEN was 8.5 months. Only a quarter of the patients experienced complications (mostly mild gastrointestinal complications); 43.1% had died at the end of the follow-up. Conclusions: in our area, the HEN incidence was much higher than those described in the literature. HEN appears to be a safe therapy with few complications that improves the nutritional status of the patients, even with short periods of administration


Introducción: la nutrición enteral domiciliaria (NED) ha experimentado un importante desarrollo, aunque aún existe una notable carencia de información acerca de su incidencia y características. Objetivos: evaluar el estado de la NED en nuestra área. Métodos: estudio observacional y prospectivo que incluyó a todos los pacientes que iniciaron NED en el periodo de un año. Describimos su evolución epidemiológica, funcional y nutricional y calculamos la incidencia de NED. Resultados: la incidencia de NED alcanzó los 229/100.000 habitantes/año. La población con NED se caracterizó por ser añosa, con una elevada frecuencia de comorbilidad y limitación funcional. Las enfermedades neurológicas y oncológicas representaron el 50% de las indicaciones. El resto fueron pacientes malnutridos que recibieron periodos cortos de NED tras una hospitalización o fractura de cadera. Los suplementos orales con fórmulas estándar o hipercalóricas fueron los más utilizados (60%). Al inicio, el 75% de los pacientes tenía malnutrición. En el seguimiento, los pacientes lograron aumento de peso (1,6%) y mayor porcentaje de normopeso o sobrepeso (de 74% a 82,7%, p = 0,001). Las úlceras por presión se redujeron (15,7% vs. 10,3%, p < 0,001). La duración mediana de NED fue 8,5 meses. Solo una cuarta parte de los pacientes experimentaron complicaciones, la mayoría de ellas gastrointestinales y leves. El 43,1% había fallecido al final del seguimiento. Conclusiones: en nuestra área, la incidencia de NED es más elevada respecto a lo descrito en la literatura. La NED es un tratamiento seguro con pocas complicaciones que mejora el estado nutricional de los pacientes, incluso con periodos cortos de administración


Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Nutrición Enteral/estadística & datos numéricos , Factores de Edad , Comorbilidad , Nutrición Enteral/efectos adversos , Nutrición Enteral/mortalidad , Servicios de Atención de Salud a Domicilio , Incidencia , Desnutrición/epidemiología , Desnutrición/terapia , Estudios Prospectivos , España/epidemiología
10.
Nutr. hosp ; 32(1): 215-221, jul. 2015. tab, ilus
Artículo en Inglés | IBECS (España) | ID: ibc-141363

RESUMEN

Introduction: home artificial nutrition (HAN) is a growing therapy, but the absence of obligatory registries complicates the calculation of its real economic burden. The aim of this study was to assess the state and economic impact of HAN in our health area. Methods: an observational, prospective study was designed to calculate the cost of nutritional formulas and materials in patients who initiated HAN in the nutrition unit during a year. Results: we included 573 new patients with HAN during the study period, 60% of whom were treated with oral supplements. The median daily cost of oral HAN was 3.65 (IQR 18.63) euros compared to a cost of 8.86 (IQR 20.02) euros for enteral-access HAN. The daily expenditure per 1 000 kcal of diet was higher for patients on oral HAN than for patients with tubes (5.13 vs. 4.52 euros, p <0.001). The median cost of the complete HAN treatments during the study period was also calculated (186.60 euros and 531.99 euros for oral and tube HAN, respectively). The total estimated cost for all patients who initiated HAN in the study period was around one million euros. Conclusions: HAN represented an important economic burden in our health area, but the estimated daily cost of HAN was moderate, probably because of the high frequency of oral HAN, the adjusted treatments, and the centralized dispensation by the hospital pharmacy (AU)


Introducción: la nutrición artificial domiciliaria (NAD) es una terapia en creciente desarrollo, pero la ausencia de registros obligatorios hace difícil calcular la carga econó- mica que implica. Nuestro objetivo es evaluar el estado y el impacto económico de la NAD en nuestra área sanitaria. Métodos: estudio observacional y prospectivo diseñado para estimar el gasto en fórmulas y materiales nutricionales en los pacientes que iniciaron NAD durante 1 año. Resultados: se incluyeron 573 pacientes que iniciaron NAD en el período de estudio. El 60% recibieron suplementos orales. La mediana de gasto diario fue de 3,65 (RIC 18,63) euros en la NAD oral y de 8,86 (RIC 20,02) euros en la NAD por acceso enteral. El gasto por 1.000 kcal de dieta fue superior en los pacientes con NAD oral respecto a los pacientes con NAD enteral (5,13 vs. 4,52 euros, p<0.001). Asimismo se calculó la mediana de gasto completo de los tratamientos durante todo el período de estudio (186,60 euros y 531,99 euros en NAD oral y enteral, respectivamente). Considerando el gasto conjunto de todos los pacientes que iniciaron NAD en el período de estudio, el gasto estimado estaría en torno a un millón de euros. Conclusiones: la NAD representa una importante carga económica en nuestra área sanitaria. Sin embargo, el gasto diario estimado fue moderado, probablemente por la elevada proporción de NAD oral en nuestra muestra, la revisión frecuente de la indicación y la centralización de la dispensación desde el servicio de Farmacia Hospitalaria (AU)


Asunto(s)
Humanos , Nutrición Parenteral en el Domicilio/métodos , Apoyo Nutricional/métodos , Trastornos Nutricionales/dietoterapia , Costo de Enfermedad , Servicio de Farmacia en Hospital/métodos , Soluciones para Nutrición Parenteral/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA